ID

32039

Description

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00604279

Lien

https://clinicaltrials.gov/show/NCT00604279

Mots-clés

Versions (1)
  1. 15/10/2018 15/10/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

15 octobre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Schizophrenia NCT00604279

Anglais

Eligibility Schizophrenia NCT00604279

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants who meet diagnostic criteria for schizophrenia according to diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) (disorganized type [295.10], catatonic type [295.20], paranoid type [295.30], residual type [295.60], or undifferentiated type [295.90]) for at least 1 year before screening and prior medical records, written documentation, or verbal information obtained from previous psychiatric providers obtained by the investigator must be consistent with the diagnosis of schizophrenia
Description

Schizophrenia Disease length | Schizophrenia, Disorganized | Schizophrenia, Catatonic | Paranoid Schizophrenia | Residual schizophrenia | Undifferentiated schizophrenia | Medical Records Consistent with Schizophrenia | Documentation Consistent with Schizophrenia | Verbal information Consistent with Schizophrenia

Type de données

boolean

Alias
UMLS CUI [1,1]
C0036341
UMLS CUI [1,2]
C0872146
UMLS CUI [2]
C0036347
UMLS CUI [3]
C0036344
UMLS CUI [4]
C0036349
UMLS CUI [5]
C0036351
UMLS CUI [6]
C0392322
UMLS CUI [7,1]
C0025102
UMLS CUI [7,2]
C0332290
UMLS CUI [7,3]
C0036341
UMLS CUI [8,1]
C0175636
UMLS CUI [8,2]
C0332290
UMLS CUI [8,3]
C0036341
UMLS CUI [9,1]
C1549471
UMLS CUI [9,2]
C0332290
UMLS CUI [9,3]
C0036341
a total positive and negative syndrome scale (panss) score between 60 and 120, inclusive, at screening and baseline
Description

PANSS score

Type de données

boolean

Alias
UMLS CUI [1]
C0451383
body mass index (bmi) of equal to or greater than 17.0 kilogram per meter square (kg/m^2)
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
female participants must be postmenopausal for at least 2 years, surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before study entry and throughout the study
Description

Postmenopausal state | Female Sterilization | Gender Sexual Abstinence | Gender Sexually active Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0015787
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0036899
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C0241028
UMLS CUI [4,3]
C0700589
be capable of self-administering study medication (applies to oral supplementation) or have assistance with study medication administration consistently available throughout the first 4 weeks of the study exclusion criteria:
Description

Investigational New Drugs Self Administration | Supplementation therapy Oral | Investigational New Drugs Administration Assistance

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0036589
UMLS CUI [2,1]
C1735596
UMLS CUI [2,2]
C1527415
UMLS CUI [3,1]
C0013230
UMLS CUI [3,2]
C1533734
UMLS CUI [3,3]
C1269765
a primary, active dsm-iv diagnosis on axis i other than schizophrenia
Description

Exclusion Criteria | Axis I diagnosis Primary | Exception Schizophrenia

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0270287
UMLS CUI [2,2]
C0205225
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0036341
a decrease of at least 25 percent in the total panss score between screening and baseline
Description

Exclusion Criteria | PANSS score Decrease Percentage

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0451383
UMLS CUI [2,2]
C0547047
UMLS CUI [2,3]
C0439165
participants who have previously participated in this study
Description

Exclusion Criteria | Study Subject Participation Status

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C2348568
a dsm-iv diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)
Description

Exclusion Criteria | Substance Dependence | Exception Nicotine Dependence | Exception Caffeine dependence

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0038580
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0028043
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1386553
history of treatment resistance as defined by failure to respond to 2 adequate treatments with different antipsychotic medications (an adequate treatment is defined as a minimum of 6 weeks at maximum tolerated dosage)
Description

Exclusion Criteria | Treatment-resistant schizophrenia | Antipsychotic Agents Different Quantity | Antipsychotic Agents Maximum Tolerated Dose | Response failed

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C3544321
UMLS CUI [3,1]
C0040615
UMLS CUI [3,2]
C1705242
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C0040615
UMLS CUI [4,2]
C0752079
UMLS CUI [5,1]
C1704632
UMLS CUI [5,2]
C0231175
Retour au début de la page

Similar models

Eligibility Schizophrenia NCT00604279

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Schizophrenia Disease length | Schizophrenia, Disorganized | Schizophrenia, Catatonic | Paranoid Schizophrenia | Residual schizophrenia | Undifferentiated schizophrenia | Medical Records Consistent with Schizophrenia | Documentation Consistent with Schizophrenia | Verbal information Consistent with Schizophrenia
Item
participants who meet diagnostic criteria for schizophrenia according to diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) (disorganized type [295.10], catatonic type [295.20], paranoid type [295.30], residual type [295.60], or undifferentiated type [295.90]) for at least 1 year before screening and prior medical records, written documentation, or verbal information obtained from previous psychiatric providers obtained by the investigator must be consistent with the diagnosis of schizophrenia
boolean
C0036341 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0036347 (UMLS CUI [2])
C0036344 (UMLS CUI [3])
C0036349 (UMLS CUI [4])
C0036351 (UMLS CUI [5])
C0392322 (UMLS CUI [6])
C0025102 (UMLS CUI [7,1])
C0332290 (UMLS CUI [7,2])
C0036341 (UMLS CUI [7,3])
C0175636 (UMLS CUI [8,1])
C0332290 (UMLS CUI [8,2])
C0036341 (UMLS CUI [8,3])
C1549471 (UMLS CUI [9,1])
C0332290 (UMLS CUI [9,2])
C0036341 (UMLS CUI [9,3])
PANSS score
Item
a total positive and negative syndrome scale (panss) score between 60 and 120, inclusive, at screening and baseline
boolean
C0451383 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) of equal to or greater than 17.0 kilogram per meter square (kg/m^2)
boolean
C1305855 (UMLS CUI [1])
Postmenopausal state | Female Sterilization | Gender Sexual Abstinence | Gender Sexually active Contraceptive methods
Item
female participants must be postmenopausal for at least 2 years, surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before study entry and throughout the study
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0036899 (UMLS CUI [3,2])
C0079399 (UMLS CUI [4,1])
C0241028 (UMLS CUI [4,2])
C0700589 (UMLS CUI [4,3])
Investigational New Drugs Self Administration | Supplementation therapy Oral | Investigational New Drugs Administration Assistance
Item
be capable of self-administering study medication (applies to oral supplementation) or have assistance with study medication administration consistently available throughout the first 4 weeks of the study exclusion criteria:
boolean
C0013230 (UMLS CUI [1,1])
C0036589 (UMLS CUI [1,2])
C1735596 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0013230 (UMLS CUI [3,1])
C1533734 (UMLS CUI [3,2])
C1269765 (UMLS CUI [3,3])
Exclusion Criteria | Axis I diagnosis Primary | Exception Schizophrenia
Item
a primary, active dsm-iv diagnosis on axis i other than schizophrenia
boolean
C0680251 (UMLS CUI [1])
C0270287 (UMLS CUI [2,1])
C0205225 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0036341 (UMLS CUI [3,2])
Exclusion Criteria | PANSS score Decrease Percentage
Item
a decrease of at least 25 percent in the total panss score between screening and baseline
boolean
C0680251 (UMLS CUI [1])
C0451383 (UMLS CUI [2,1])
C0547047 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
Exclusion Criteria | Study Subject Participation Status
Item
participants who have previously participated in this study
boolean
C0680251 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Exclusion Criteria | Substance Dependence | Exception Nicotine Dependence | Exception Caffeine dependence
Item
a dsm-iv diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)
boolean
C0680251 (UMLS CUI [1])
C0038580 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0028043 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1386553 (UMLS CUI [4,2])
Exclusion Criteria | Treatment-resistant schizophrenia | Antipsychotic Agents Different Quantity | Antipsychotic Agents Maximum Tolerated Dose | Response failed
Item
history of treatment resistance as defined by failure to respond to 2 adequate treatments with different antipsychotic medications (an adequate treatment is defined as a minimum of 6 weeks at maximum tolerated dosage)
boolean
C0680251 (UMLS CUI [1])
C3544321 (UMLS CUI [2])
C0040615 (UMLS CUI [3,1])
C1705242 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0040615 (UMLS CUI [4,1])
C0752079 (UMLS CUI [4,2])
C1704632 (UMLS CUI [5,1])
C0231175 (UMLS CUI [5,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial